Search

Compact and safe charging platforms have been one of the main goals in wireless power transfer (WPT) research and development. Here we propose a compact hybrid metasurface-inspired resonator with a uniform magnetic field distribution for WPT. It consists of two orthogonally oriented layers of parallel printed wires with high-permittivity dielectric pads between them. This design allows to spatially separate electric and magnetic fields, which provide high WPT efficiency and electromagnetic safety simultaneously. The prototype with 28~cm~ $\times$ ~28~cm working area with uniform magnetic field was fabricated and experimentally studied. The measured coefficient of variation of the magnetic field in the working area of the resonator is 6.8\%. The maximum achievable WPT efficiency reaches 70\% over the working area. The numerically assessed specific absorption rate in human tissues placed on the proposed structure is 11~mW/kg, which is 30 times lower than on a conventional planar spiral coil. Our results pave the way to compact and safe WPT platforms for one-to-many charging occasions.

The paper is devoted to the issue of blood donation and possible ways to promote this activity using modern information technologies. Existing software solutions are analyzed and new Web application is proposed to implement all features required for potential blood donors to make this process clearer and more comfortable.

Wireless power transfer—the transmission of electromagnetic energy without physical connectors such as wires or waveguides—typically exploits electromagnetic field control methods that were first proposed decades ago and requires some essential parameters (such as efficiency) to be sacrificed in favour of others (such as stability). In recent years, novel approaches to electromagnetic field manipulation have been developed that can be used to create advanced forms of wireless power transfer. Here we review the development of novel physical effects and materials for wireless power transfer. We explore techniques based on coherent perfect absorption, parity–time symmetry and exceptional points, and on-site power generation. We also explore the use of metamaterials and metasurfaces in wireless power transfer, and the use of acoustic power transfer. Finally, we highlight potential routes for the further development of wireless power transfer technology. This Review examines the development of novel physical effects and materials for wireless power transfer, considering techniques based on coherent perfect absorption, parity–time symmetry and exceptional points, and on-site power generation, as well as the use of metamaterials and metasurfaces, and acoustic power transfer.

Last year, in Russia there was started a new government long-term initiative, that aims reduction for Russian greenhouse gas emissions by up to 70 percent compared to the 1990 level in less than next 10 years (by 2030).On the one hand such ambitious goal to includes massive technical and industrial modernization and other hand – supposed to provide valid, verified and globally recognized scientific data on the runoff and emission of greenhouse gases from ecosystems all around Russia. Thus, a large-scale program for the development of carbon stations has started with running of carbon polygons, which should combine both research-methodological and educational functions, and, eventually, contribute to the achievement of the specified state objective. The educational function of the polygons includes training personnel with interdisciplinary competencies to work on "carbon" topics, including the highest qualifications.Starting to design and equip the first running polygon in the Tyumen region (by University of Tyumen), we initially stated concept of creating an ecological and climatic transect across the whole of Russia from north to south. The general idea is connect the new carbon polygon near Tyumen with carbon monitor infrastructure in proposed polygons and stations in Tobolsk and Ishim, Khanty-Mansiysk (Mukhrino) and Yamalo-Nenets (Labytnangi)Autonomous Disctricts. With potential sites in partners, that University of Tyumen has in Central Asian republics, there are prospect to continue this meridional transect further to the south. And in this case, we have the prospect of getting a global-scale monitoring system in the center of Eurasia across all natural zones from north to south, that provide massive raw data set for global observation system.

The thermal behaviour of Ag2[PtCl4] and Ag2[PtCl6] complex salts in inert and reducing atmospheres has been studied. The thermolysis of compounds in a helium atmosphere is shown to occur in two stages. At the first stage, the complexes decompose in the temperature range of 350-500°C with the formation of platinum and silver chloride and the release of chlorine gas. At the second stage, silver chloride is sublimated in the temperature range of 700-900 °C, while metallic platinum remains in the solid phase. In contrast to the thermolysis of Ag2[PtCl6], the thermal decomposition of Ag2[PtCl4] at 350 °C is accompanied by significant heat release, which is associated with disproportionation of the initial salt to Ag2[PtCl6], silver chloride, and platinum metal. It is confirmed by DSC measurements, DFT calculations of a suggested reaction, and XRD. The thermolysis of Ag2[PtCl6] and Ag2[PtCl6] compounds is established to occur in a hydrogen atmosphere in two poorly separable steps. The compounds are decomposed within 170-350°C, and silver and platinum are reduced to a metallic state, while a metastable single-phase solid solution of Ag0.67Pt0.33 is formed. The catalytic activity of the resulting nanoalloy Ag0.67Pt0.33 is studied in the reaction of CO total (TOX) and preferential (PROX) oxidation. Ag0.67Pt0.33 advanced Pt nanopowder in activity in CO TOX, but was not selective in CO PROX.

Specific traits of the U.S. policies in Eastern Europe in the first months of the Joe Biden presidency are pre-determined primarily by the Democrats’ desire to normalize the U.S. relationship with the major Western European allies and the EU as a whole, spoiled under Donald Trump. This task makes it necessary to abandon artificial opposing of Eastern Europe to Western Europe. The Biden administration attaches major importance to the issue of common liberal values, which creates certain problems in relations with some East European governments, like Hungary or Poland. Political and diplomatic steps of the new administration in the region, both in a bilateral format and through multilateral forums (in particular the Three Seas Initiative), have revealed, on the one hand, the U.S. desire to keep protecting the security of the region in the face of the Russian and, increasingly Chinese, challenge; on the other hand, lower priority attached to "energy wars" with Russia, gradual waiving of sanctions on the Nord Stream 2 pipeline project, as well as Biden's unwillingness to sacrifice relations with Germany and other Western European allies for the sake of specific interests of countries like Poland, which were conceived by the Trump administration as a counterweight to Western Europe.

Background The additional benefit of methotrexate (MTX) as a concomitant treatment in PsA has not been fully elucidated for TNF inhibitors (TNFi) and no real-world data on this currently exist for ustekinumab (UST). We investigated the additive effect of MTX on the ability to reach composite treatment targets beyond monotherapy with UST or TNFi, and the ability to improve patient-reported outcomes in a real-world clinical setting in 8 European countries. Methods The PsABio study (NCT02627768) evaluates persistence, effectiveness and tolerability of 1st, 2nd or 3rd-line UST or TNFi in patients with PsA. Proportions of patients reaching minimal disease activity (MDA)/very low disease activity (VLDA) and clinical Disease Activity in Psoriatic Arthritis (cDAPSA) low disease activity (LDA) or remission, as well as the patient acceptable symptom state (PASS; score ≤4) of the 12-item Psoriatic Arthritis Impact of Disease questionnaire (PsAID-12) were evaluated. Here we present 6-month follow-up data using intention to treat (ITT) analysis; patients who stopped/switched initial treatment were imputed as non-responders. The effect of MTX co-therapy was investigated within UST and TNFi cohorts, as well as between the cohorts, using multivariate logistic regression including interaction terms, and propensity score (PS) analysis to adjust for imbalanced, potentially prognostic, baseline covariates. Results Of 930 patients, data was available for 868 ITT patients, including patients who switched/stopped before 6 months (UST: n = 28/426 [6.6%], TNFi: n = 44/442 [10.0%]). At baseline there were no relevant differences in demographics and disease activity, however there were significant differences in skin involvement as well as csDMARD and NSAID exposure. Co-therapy with MTX did not increase the likelihood of achieving any of the outcomes in either the UST or TNFi cohorts (Table 1). After PS adjustment, co-treatment with MTX did not influence treatment effects differently when added to UST compared with TNFi. concomitant use of csDMARDs other than MTX yielded very similar results. Conclusion In a real-world setting, concomitant treatment with MTX in addition to UST or TNFi was not associated with enhanced effects across a broad variety of disease outcomes, including disease activity, disease impact, and skin involvement within or between treatment cohorts, after PS adjustment for baseline confounders. Disclosures S. Siebert: Consultancies; AbbVie, UCB, Pfizer, Janssen, Boehringer Ingelheim, Celgene, Novartis. Grants/research support; Pfizer, Janssen, BMS, Celgene, UCB, Boehringer Ingelheim. E. Gremese: Consultancies; AbbVie, BMS, Celgene, Janssen, Lilly, MSD, Novartis, Sanofi, UCB, Roche, Pfizer. P. Bergmans: Shareholder/stock ownership; Johnson & Johnson. Other; Employee of Janssen. K. de Vlam: Consultancies; Johnson & Johnson. B. Joven-Ibáñez: Member of speakers’ bureau; Celgene, Novartis, MSD, Pfizer, AbbVie, Janssen. G. Katsifis: None. T.V. Korotaeva: Consultancies; Pfizer, MSD, Novartis, AbbVie, Celgene, Biocad, Janssen, UCB, Lilly, Novartis-Sandoz. W. Noël: Other; Employee of Janssen. C. Selmi: None. P.P. Sfikakis: None. P. Smirnov: Other; Employee of Janssen. E. Theander: Other; Employee of Janssen. M.T. Nurmohamed: Grants/research support; Pfizer, AbbVie, Roche, BMS, MSD, Mundipharma, UCB, Janssen, Menarini, Lilly, Sanofi, Celgene. L. Gossec: Honoraria; AbbVie, Celgene, Janssen, Lilly, Novartis-Sandoz, Pfizer, Sanofi, UCB. Grants/research support; Pfizer. J.S. Smolen: Consultancies; AbbVie, Amgen, AstraZeneca, Astro, Celgene, Celtrion, GlaxoSmithKline, ILTOO Pharma, Janssen, Lilly, Medimmune, MSD, Novartis-Sandoz, Pfizer, Roche, Samsung, Sanofi, UCB. Grants/research support; AbbVie, Janssen, Lilly, MSD, Pfizer, Roche.

The paper proposes a block method for estimating the deformation field for image sequences using a stochastic adaptation procedure. As a target function, the paper considers mean square inter-frame difference and interframe correlation coefficient. The developed algorithm has a high noise resistance and allows one to reduce the influence of global inter-frame geometric changes. Also, by adjusting the size of the blocks, it makes it possible to remove or highlight moving objects of small size (rain, snow, falling leaves, etc.).

Background The link between obesity and disease activity in PsA is unclear. Obesity has been associated with a poorer therapeutic response and higher treatment discontinuation rates in patients with PsA being treated with tumour necrosis factor inhibitors (TNFi). Recent data confirm the favourable effect of weight reduction on these factors. There are no data available for other biologics. Objectives To investigate the relationship between baseline overweight/obesity and disease activity, patient-reported outcomes and disability, in a large real-world cohort of patients with PsA starting biologic treatment with either ustekinumab (UST) or TNFi. Methods The PsABio study (ClinicalTrials.gov: NCT02627768) is an ongoing observational study evaluating efficacy, tolerability and persistence of 1st, 2nd- and 3rd-line UST or TNFi in PsA in 8 European countries1 when introduced as part of standard clinical care. Baseline data of the study population were collected and analysed for BMI, disease activity (cDAPSA, psoriasis BSA), patient-perceived impact (PsAID-12), disability (HAQ-DI) and presence or history of CVD/MET. Descriptive statistics on available data and 3 exploratory multiple regression models are shown, to investigate the relationship of cDAPSA, PsAID-12 and HAQ-DI (dependent variables) with BMI, adjusted for age, sex, smoking, BSA, CRP, disease duration and biologic treatment. Results In all, 917 patients were included, starting either UST (n=450) or TNFi (n=467): mean (SD) age 49.7 (12.5) years, 55.5% female. The mean (SD) baseline BMI (N=827) was 28.1 (5.8) kg/m2, with 40.0% and 30.4% in BMI categories overweight (>25–30) and obese (>30), respectively. In univariate analyses, obesity was linked to worse outcomes (Table 1). More severe disease was associated with higher BMI (Table 2). In multiple regression modelling, higher BMI was independently linked to higher cDAPSA (BMI: β=0.09 p=0.026); to higher patient-perceived disease impact measured by PsAID-12 (BMI: β=0.16, p Conclusion This multi-country routine-care PsA cohort of patients in need of biologic treatment confirms the high prevalence of overweight/obesity and indicates an independent association between high BMI and disease activity as well as patient-reported impact of disease and disability. These results emphasize the need for lifestyle-directed approaches in PsA, such as overweight management in parallel with joint- and skin-focused treatment. Reference [1] Gossec L, et al. Ann Rheum Dis. 2018;77(Suppl):A1033. Acknowledgement This study was sponsored by Janssen Disclosure of Interests Stefan Siebert Grant/research support from: AbbVie, Novartis, Pfizer, Janssen, BMS, Celgene, UCB, and Boehringer Ingelheim, Consultant for: AbbVie, UCB, Pfizer, Janssen, Boehringer Ingelheim, Celgene, and Novartis, Speakers bureau: AbbVie, UCB, Pfizer, Janssen, Boehringer Ingelheim, Celgene, and Novartis, Paul Bergmans Shareholder of: Johnson & Johnson, Employee of: Janssen, Kurt de Vlam Consultant for: Pfizer Inc, Consultant for: Johnson & Johnson, Elisa Gremese Consultant for: AbbVie, BMS, Celgene, Janssen, Lilly, MSD, Novartis, Sanofi, UCB, Roche, and Pfizer, Speakers bureau: BMS, Speakers bureau: Roche, Speakers bureau: AbbVie, BMS, Celgene, Janssen, Lilly, MSD, Novartis, Sanofi, UCB, Roche, and Pfizer, Beatriz Joven-Ibanez Speakers bureau: Celgene, Novartis, MSD, Pfizer, AbbVie, and Janssen, Tatiana Korotaeva Consultant for: Pfizer, MSD, Novartis, AbbVie, Celgene, Biocad, Janssen, UCB, Lilly and Novartis-Sandoz, Speakers bureau: Pfizer, MSD, Novartis, AbbVie, Celgene, Biocad, Janssen, UCB, Lilly and Novartis-Sandoz, Wim Noel Employee of: Janssen, M.T. Nurmohamed Grant/research support from: Pfizer, AbbVie, Roche, BMS, MSD, Mundipharma, UCB, Janssen, Menarini, Lilly, Sanofi, and Celgene., Grant/research support from: Pfizer, Abbvie, Roche, BMS, MSD, Mundipharma, UCB, Janssen, Menarini, Eli Lilly, Celgene & Sanofi, Consultant for: Pfizer, AbbVie, Roche, BMS, MSD, Mundipharma, UCB, Janssen, Menarini, Lilly, Sanofi, and Celgene., Speakers bureau: Pfizer, AbbVie, Roche, BMS, MSD, Mundipharma, UCB, Janssen, Menarini, Lilly, Sanofi, and Celgene., Speakers bureau: Pfizer, Abbvie, Roche, BMS, MSD, Mundipharma, UCB, Janssen, Menarini, Eli Lilly, Celgene & Sanofi, Petros Sfikakis: None declared, Ana Laiz Consultant for: Lilly, Novartis, AbbVvie, MSD, UCB and Janssen, Speakers bureau: Lilly, Novartis, Abvvie, MSD, UCB and Janssen, Pavel Smirnov Employee of: Janssen, Elke Theander Employee of: Janssen, Josef S. Smolen Grant/research support from: AbbVie, Eli Lilly, Janssen, MSD, Pfizer Inc, Roche, Consultant for: AbbVie, Amgen, AstraZeneca, Astro, Celgene, Celtrion, Eli Lilly, GlaxoSmithKline, ILTOO, Janssen, Medimmune, MSD, Novartis-Sandoz, Pfizer Inc, Roche, Samsung, Sanofi, UCB, Speakers bureau: AbbVie, Amgen, AstraZeneca, Astro, Celgene, Celtrion, Eli Lilly, GlaxoSmithKline, ILTOO, Janssen, Medimmune, MSD, Novartis-Sandoz, Pfizer Inc, Roche, Samsung, Sanofi, UCB, Laure Gossec Grant/research support from: AbbVie, BMS, Celgene, Janssen, Lilly, MSD, Novartis-Sandoz, Pfizer, Sanofi, and UCB, Consultant for: AbbVie, Biogen, BMS, Celgene, Janssen, Lilly, MSD, Nordic Pharma, Novartis-Sandoz, Pfizer, Roche, Sanofi, and UCB, Consultant for: L Gossec has received honoraria from Celgene as investigator for this study

Background The link between reaching a state of remission or LDA1,2 and patient-reported outcomes in PsA has been little explored in an observational setting. Objectives This analysis investigates the potential effect of reaching remission or LDA according to cDAPSA and achievement of VLDA/MDA on patient-reported outcomes such as HRQoL, functioning and pain in an observational cohort of PsA patients. Methods PsABio (NCT02627768) is an ongoing real-world observational study in 8 European countries where PsA patients receive 1st-, 2nd- or 3rd-line biologics (starting either ustekinumab [UST] or a TNFi. Of 563 UST- or TNFi-treated patients enrolled Dec 2015 – Aug 2017, 303 had data available from their 6-month follow-up. Disease states were defined using cDAPSA ≤4 for remission and ≤13 for LDA (data available for 250 patients) and VLDA 7/7 and MDA 5/7 criteria (data available for 206 and 260 patients, respectively). HRQoL was assessed by the generic instrument EQ5D and the PsA specific tool PsAID-12. Physical functioning was measured by the HAQ-DI and pain with a Pain VAS (0–100). Assessment of Psoriasis Skin Disease (68/299=22.7%) was the most frequently missed MDA component, while enthesitis was the least frequently missed (6/299=2.0%). The other 5 components were all missed with equal frequency (8–9%). Available observed data on univariate associations are presented, with no imputation of missing data or adjustment for baseline imbalances. Results For the 303 patients, mean age was 49.7 (standard deviation [SD] 12.8) years, mean disease duration was 7.2 (SD, 8.2) years, and 50.5% were women. Figure 1 shows data at 6 months for cDAPSA remission, cDAPSA LDA, VLDA, and MDA in UST- and TNFi-treated patients. Start of treatment with either UST or TNFi did not significantly influence the rates of these outcomes at 6 months. cDAPSA remission/LDA and VLDA/MDA achievement (Yes vs No) was associated with better general and disease-specific HRQoL assessments, (EQ5D VAS, PsAID-12) physical function (HAQ-DI) and Pain (VAS) shown by non-overlapping confidence intervals in Figure 2. Conclusion In real-life, treatment with either UST or a TNFi leads to considerable and comparable numbers of patients reaching LDA or remission. Reaching such LDA is associated with clinically important improvements exceeding minimal clinically important differences for QoL, functioning and pain experience. Our data therefore strongly support a treat-to-target strategy in routine care for PsA. References [1] Gossec L, et al. Ann Rheum Dis. 2016;75:499–510; 2. Smolen JS,et al. Ann Rheum Dis. 2018;77:3–17. Acknowledgement This study was sponsored by Janssen Disclosure of Interests Laure Gossec Grant/research support from: AbbVie, BMS, Celgene, Janssen, Lilly, MSD, Novartis-Sandoz, Pfizer, Sanofi, and UCB, Consultant for: AbbVie, Biogen, BMS, Celgene, Janssen, Lilly, MSD, Nordic Pharma, Novartis-Sandoz, Pfizer, Roche, Sanofi, and UCB, Consultant for: L Gossec has received honoraria from Celgene as investigator for this study, Paul Bergmans Shareholder of: Johnson & Johnson, Employee of: Janssen, Kurt de Vlam Consultant for: Pfizer Inc, Consultant for: Johnson & Johnson, Elisa Gremese Consultant for: AbbVie, BMS, Celgene, Janssen, Lilly, MSD, Novartis, Sanofi, UCB, Roche, and Pfizer, Speakers bureau: BMS, Speakers bureau: Roche, Speakers bureau: AbbVie, BMS, Celgene, Janssen, Lilly, MSD, Novartis, Sanofi, UCB, Roche, and Pfizer, Beatriz Joven-Ibanez Speakers bureau: Celgene, Novartis, MSD, Pfizer, AbbVie, and Janssen, Tatiana Korotaeva Consultant for: Pfizer, MSD, Novartis, AbbVie, Celgene, Biocad, Janssen, UCB, Lilly and Novartis-Sandoz, Speakers bureau: Pfizer, MSD, Novartis, AbbVie, Celgene, Biocad, Janssen, UCB, Lilly and Novartis-Sandoz, Wim Noel Employee of: Janssen, M.T. Nurmohamed Grant/research support from: Pfizer, AbbVie, Roche, BMS, MSD, Mundipharma, UCB, Janssen, Menarini, Lilly, Sanofi, and Celgene., Grant/research support from: Pfizer, Abbvie, Roche, BMS, MSD, Mundipharma, UCB, Janssen, Menarini, Eli Lilly, Celgene & Sanofi , Consultant for: Pfizer, AbbVie, Roche, BMS, MSD, Mundipharma, UCB, Janssen, Menarini, Lilly, Sanofi, and Celgene., Speakers bureau: Pfizer, AbbVie, Roche, BMS, MSD, Mundipharma, UCB, Janssen, Menarini, Lilly, Sanofi, and Celgene., Speakers bureau: Pfizer, Abbvie, Roche, BMS, MSD, Mundipharma, UCB, Janssen, Menarini, Eli Lilly, Celgene & Sanofi , Petros Sfikakis: None declared, Stefan Siebert Grant/research support from: AbbVie, Novartis, Pfizer, Janssen, BMS, Celgene, UCB, and Boehringer Ingelheim, Consultant for: AbbVie, UCB, Pfizer, Janssen, Boehringer Ingelheim, Celgene, and Novartis, Speakers bureau: AbbVie, UCB, Pfizer, Janssen, Boehringer Ingelheim, Celgene, and Novartis, Pavel Smirnov Employee of: Janssen, Elke Theander Employee of: Janssen, Josef S. Smolen Grant/research support from: AbbVie, Eli Lilly, Janssen, MSD, Pfizer Inc, Roche, Consultant for: AbbVie, Amgen, AstraZeneca, Astro, Celgene, Celtrion, Eli Lilly, GlaxoSmithKline, ILTOO, Janssen, Medimmune, MSD, Novartis-Sandoz, Pfizer Inc, Roche, Samsung, Sanofi, UCB, Speakers bureau: AbbVie, Amgen, AstraZeneca, Astro, Celgene, Celtrion, Eli Lilly, GlaxoSmithKline, ILTOO, Janssen, Medimmune, MSD, Novartis-Sandoz, Pfizer Inc, Roche, Samsung, Sanofi, UCB